Загрузка...
Levoketoconazole improves clinical signs and symptoms and patient-reported outcomes in patients with Cushing’s syndrome
PURPOSE: The efficacy of levoketoconazole in treating hypercortisolism was demonstrated in an open-label phase 3 study (SONICS) of adults with endogenous Cushing’s syndrome (CS) and baseline mean urinary free cortisol (mUFC) ≥ 1.5× ULN. Clinical signs and symptoms and patient-reported outcomes from...
Сохранить в:
| Опубликовано в: : | Pituitary |
|---|---|
| Главные авторы: | , , , , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Springer US
2020
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7864823/ https://ncbi.nlm.nih.gov/pubmed/33216275 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11102-020-01103-6 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|